Padraig Warde

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. pmc Image guided dose escalated prostate radiotherapy: still room to improve
    Jarad M Martin
    Princess Margaret Hospital, Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    Radiat Oncol 4:50. 2009
  2. pmc Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial
    Padraig Warde
    Princess Margaret Hospital, Toronto, Canada
    Lancet 378:2104-11. 2011
  3. ncbi request reprint A randomized phase III study of neoadjuvant hormonal therapy in patients with localized prostate cancer
    Padraig Warde
    Department of Radiation Oncology, Princess Margaret Hospital Ontario, Canada
    Clin Genitourin Cancer 5:235-7. 2006
  4. ncbi request reprint Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis
    Padraig Warde
    Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 20:4448-52. 2002
  5. ncbi request reprint A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer
    Padraig Warde
    Department of Radiation Oncology, Princess Margaret Hospital, University Health Network, 610 University Avenue, 5th Floor, Toronto, Ontario M5G 2M9, Canada
    Int J Radiat Oncol Biol Phys 54:9-13. 2002
  6. ncbi request reprint Adjuvant carboplatin in stage I seminoma
    Padraig Warde
    Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, M5G 2M9, Canada
    Lancet 366:267-8. 2005
  7. doi request reprint Management of localized seminoma, stage I-II: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009
    P Warde
    Department of Radiation Oncology, University of Toronto, Radiation Medicine Program, Princess Margaret Hospital, Toronto, Ontario, Canada
    Urology 78:S435-43. 2011
  8. doi request reprint Clinical application of high-dose, image-guided intensity-modulated radiotherapy in high-risk prostate cancer
    Andrew Bayley
    Radiation Medicine Program, Princess Margaret Hospital, Toronto, ON, Canada
    Int J Radiat Oncol Biol Phys 77:477-83. 2010
  9. ncbi request reprint Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma
    Jarad M Martin
    Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
    Int J Radiat Oncol Biol Phys 69:1084-9. 2007
  10. doi request reprint A dose escalation study of hyperfractionated accelerated radiation delivered with integrated neck surgery (HARDWINS) for the management of advanced head and neck cancer
    John Waldron
    Department of Radiation Oncology, Princess Margaret Hospital and the University of Toronto, Canada
    Radiother Oncol 87:173-80. 2008

Detail Information

Publications81

  1. pmc Image guided dose escalated prostate radiotherapy: still room to improve
    Jarad M Martin
    Princess Margaret Hospital, Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    Radiat Oncol 4:50. 2009
    ..The primary objective was to assess 5-year biochemical control and potential prognostic factors by the Phoenix definition. Secondary endpoints included acute and late toxicity by the Radiotherapy Oncology Group (RTOG) scoring scales...
  2. pmc Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial
    Padraig Warde
    Princess Margaret Hospital, Toronto, Canada
    Lancet 378:2104-11. 2011
    ..Our aim was to compare outcomes in such patients with locally advanced prostate cancer...
  3. ncbi request reprint A randomized phase III study of neoadjuvant hormonal therapy in patients with localized prostate cancer
    Padraig Warde
    Department of Radiation Oncology, Princess Margaret Hospital Ontario, Canada
    Clin Genitourin Cancer 5:235-7. 2006
    ..In addition, patients randomized to the neoadjuvant bicalutamide arm will be asked to consider having these studies repeated before initiation of radiation therapy (after 3 months of hormonal therapy)...
  4. ncbi request reprint Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis
    Padraig Warde
    Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 20:4448-52. 2002
    ..We performed a pooled analysis of patients from the four largest surveillance studies to better delineate prognostic factors associated with disease progression...
  5. ncbi request reprint A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer
    Padraig Warde
    Department of Radiation Oncology, Princess Margaret Hospital, University Health Network, 610 University Avenue, 5th Floor, Toronto, Ontario M5G 2M9, Canada
    Int J Radiat Oncol Biol Phys 54:9-13. 2002
    ..To test the hypothesis that the use of oral pilocarpine during and after radiotherapy (RT) for head-and-neck cancer would reduce the symptoms of post-RT xerostomia...
  6. ncbi request reprint Adjuvant carboplatin in stage I seminoma
    Padraig Warde
    Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, M5G 2M9, Canada
    Lancet 366:267-8. 2005
  7. doi request reprint Management of localized seminoma, stage I-II: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009
    P Warde
    Department of Radiation Oncology, University of Toronto, Radiation Medicine Program, Princess Margaret Hospital, Toronto, Ontario, Canada
    Urology 78:S435-43. 2011
    ..It was also noted that surgery in this setting is technically challenging and could be associated with greater morbidity than in patients with nonseminomatous tumors...
  8. doi request reprint Clinical application of high-dose, image-guided intensity-modulated radiotherapy in high-risk prostate cancer
    Andrew Bayley
    Radiation Medicine Program, Princess Margaret Hospital, Toronto, ON, Canada
    Int J Radiat Oncol Biol Phys 77:477-83. 2010
    ..To report the feasibility and early toxicity of dose-escalated image-guided IMRT to the pelvic lymph nodes (LN), prostate (P), and seminal vesicles (SV)...
  9. ncbi request reprint Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma
    Jarad M Martin
    Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
    Int J Radiat Oncol Biol Phys 69:1084-9. 2007
    ..To assess in a prospective trial the feasibility and late toxicity of hypofractionated radiotherapy (RT) for prostate cancer...
  10. doi request reprint A dose escalation study of hyperfractionated accelerated radiation delivered with integrated neck surgery (HARDWINS) for the management of advanced head and neck cancer
    John Waldron
    Department of Radiation Oncology, Princess Margaret Hospital and the University of Toronto, Canada
    Radiother Oncol 87:173-80. 2008
    ..To determine toxicity and outcome of radiation dose escalation with hyperfractionated accelerated radiation delivered with neck surgery (HARDWINS) for head and neck cancer...
  11. doi request reprint Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer
    Michael Milosevic
    Radiation Medicine Program, Princess Margaret Hospital and Ontario Cancer Institute, University Health Network, 610 University Avenue, Toronto, ON, Canada M5G 2M9
    Clin Cancer Res 18:2108-14. 2012
    ..The aim of this study was to determine the effect of hypoxia in patients with prostate cancer treated with radiotherapy...
  12. ncbi request reprint Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response
    Michael Milosevic
    Radiation Medicine Program, Department of Medical Imaging, Princess Margaret Hospital, Toronto, Ontario, Canada
    Cancer Res 67:6022-5. 2007
    ....
  13. doi request reprint Treatment burden in stage I seminoma: a comparison of surveillance and adjuvant radiation therapy
    Eric Leung
    Radiation Medicine Program, Princess Margaret Hospital, Toronto, ON, Canada University of Toronto, Toronto, ON, Canada
    BJU Int 112:1088-95. 2013
    ..To examine the management and outcomes of patients with stage I seminoma and to relate these to overall treatment burden...
  14. doi request reprint Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer
    Danny Vesprini
    Radiation Medicine Program, Princess Margaret Hospital, University Health Network, and Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada
    Int J Radiat Oncol Biol Phys 83:608-16. 2012
    ..We tested the hypothesis that prospectively scored acute toxicity is associated with biochemical failure-free rate (BFFR) in prostate cancer patients treated with IGRT...
  15. doi request reprint Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy
    Danny Vesprini
    Department of Radiation Oncology, Sunnybrook Odette Cancer Center, Toronto, Ontario, Canada
    Int J Radiat Oncol Biol Phys 81:e415-21. 2011
    ....
  16. doi request reprint Hyperfractionated, accelerated radiotherapy for locally advanced head and neck cancer: quality of life in a prospective phase I/II trial
    Jolie Ringash
    Department of Radiation Oncology, The Princess Margaret Hospital, Toronto, Canada
    Radiother Oncol 87:181-7. 2008
    ..Quality of life (QOL) was measured prospectively in a dose escalation study of twice daily hyperfractionated, accelerated radiotherapy for locally advanced head and neck cancer (HNC)...
  17. doi request reprint A phase I trial of pre-operative radiotherapy for prostate cancer: clinical and translational studies
    Stephane Supiot
    Princess Margaret Hospital University Health Network, Toronto, Ont, Canada
    Radiother Oncol 88:53-60. 2008
    ..In a phase I trial, we investigated the feasibility of pre-operative radiotherapy for this patient subset...
  18. doi request reprint Validation of a predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic
    Edward Chow
    Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
    Int J Radiat Oncol Biol Phys 73:280-7. 2009
    ..To validate a predictive model for survival of patients attending a palliative radiotherapy clinic...
  19. ncbi request reprint A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy
    Alan Nichol
    Radiation Medicine Program, Princess Margaret Hospital and University of Toronto, Toronto, Canada
    Radiother Oncol 76:11-7. 2005
    ..To prospectively evaluate toxicity, biochemical failure-free survival (bFFS) and biopsy-proven local control for prostate cancer patients treated with 75.6 Gy in 42 fractions using 6-field conformal radiotherapy to prostate alone...
  20. ncbi request reprint Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy
    Masoom A Haider
    Department of Medical Imaging, University Health Network and Mount Sinai Hospital, University of Toronto, Toronto, Canada
    Int J Radiat Oncol Biol Phys 70:425-30. 2008
    ....
  21. doi request reprint Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer
    Shabbir M H Alibhai
    University Health Network, Toronto, Ontario, Canada
    J Clin Oncol 28:5038-45. 2010
    ..This prospective longitudinal study evaluated the effect of androgen deprivation therapy (ADT) on objective and self-reported physical function...
  22. ncbi request reprint Evidence-based guidelines for following stage 1 seminoma
    Jarad M Martin
    Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    Cancer 109:2248-56. 2007
    ..The authors developed evidence-based guidelines for a follow-up schedule after orchiectomy for stage 1 seminoma. Required investigations, frequency of assessment, overall duration of follow-up, and management strategies were identified...
  23. ncbi request reprint Patient-assessed late toxicity rates and principal component analysis after image-guided radiation therapy for prostate cancer
    Marketa Skala
    Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
    Int J Radiat Oncol Biol Phys 68:690-8. 2007
    ....
  24. doi request reprint Predictive model for survival in patients with advanced cancer
    Edward Chow
    Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, Ontario, Canada M4N 3M5
    J Clin Oncol 26:5863-9. 2008
    ..To derive and validate a simple predictive model for survival of patients with metastatic cancer attending a palliative radiotherapy clinic...
  25. doi request reprint Changes in apparent diffusion coefficient and T2 relaxation during radiotherapy for prostate cancer
    Warren D Foltz
    Radiation Medicine Program, Princess Margaret Hospital, and Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada
    J Magn Reson Imaging 37:909-16. 2013
    ..To evaluate regional and temporal changes in apparent diffusion coefficient (ADC) and T2 relaxation during radiation therapy (RT) in patients with low and intermediate risk localized prostate cancer...
  26. ncbi request reprint Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer
    Bernard Cummings
    Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Ontario, Canada
    Radiother Oncol 85:7-16. 2007
    ....
  27. ncbi request reprint Treatment options, prognostic factors and selection of treatment in stage I seminoma
    Jarad Martin
    Princess Margaret Hospital, Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada
    Onkologie 29:592-8. 2006
    ..It must be remembered that 80-85% of patients with testicular seminoma require no treatment after orchiectomy, and the long-term side effects of any adjuvant treatment approach must be carefully considered...
  28. doi request reprint Sex or survival: short-term versus long-term androgen deprivation in patients with locally advanced prostate cancer treated with radiotherapy
    Derek R Wilke
    Department of Radiation Oncology, Nova Scotia Cancer Center, Queen Elizabeth II Health Sciences Center, Dalhousie University, Halifax, Nova Scotia, Canada
    Cancer 116:1909-17. 2010
    ..The seminal question is whether or not the gains are worth the adverse effects of LTAD with respect to patient preferences...
  29. ncbi request reprint Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia
    Jolie Ringash
    Department of Radiation Oncology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
    Int J Radiat Oncol Biol Phys 61:1403-7. 2005
    ..To determine the relationship between quality of life (QOL) and xerostomia over time for patients undergoing radiotherapy (RT) for head-and-neck cancer in a prospective clinical trial...
  30. doi request reprint Healthcare costs associated with prostate cancer: estimates from a population-based study
    Murray D Krahn
    Department of Medicine, University of Toronto, Toronto, Canada
    BJU Int 105:338-46. 2010
    ..Health Economic (multiway sensitivity analyses)...
  31. doi request reprint Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men
    Shabbir M H Alibhai
    Division of General Internal Medicine and Clinical Epidemiology and Osteoporosis Program, University Health Network, Toronto, Ontario, Canada
    J Urol 184:918-23. 2010
    ..One study suggested that androgen deprivation therapy may also be associated with nonfragility fractures in older men. Whether other clinical risk factors independently increase the risk of fractures is not certain...
  32. ncbi request reprint Recurrent prostate cancer following external beam radiotherapy: follow-up strategies and management
    Charles Catton
    Department of Radiation Oncology, University of Toronto, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
    Urol Clin North Am 30:751-63. 2003
    ....
  33. doi request reprint Pathological predictors for site of local recurrence after radiotherapy for prostate cancer
    Supriya Chopra
    Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada
    Int J Radiat Oncol Biol Phys 82:e441-8. 2012
    ..We sought to identify pathological factors predictive for site of local recurrence (LR) after external beam RT...
  34. ncbi request reprint Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy
    Kirsty L Wiltshire
    Radiation Medicine Program, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    Int J Radiat Oncol Biol Phys 69:1090-9. 2007
    ..We sought to derive and validate an interdisciplinary consensus definition for the anatomic boundaries of the postoperative clinical target volume (CTV, prostate bed)...
  35. doi request reprint Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer
    Shabbir M H Alibhai
    University Health Network, Toronto, Ontario, Canada
    J Clin Oncol 28:5030-7. 2010
    ..To evaluate the effects of androgen-deprivation therapy (ADT) on cognitive function in men with nonmetastatic prostate cancer (PC)...
  36. ncbi request reprint Comparison of low dose with standard dose abdominal/pelvic multidetector CT in patients with stage 1 testicular cancer under surveillance
    Martin E O'Malley
    Joint Department of Medical Imaging, Princess Margaret Hospital, Toronto, ON, Canada
    Eur Radiol 20:1624-30. 2010
    ..To compare the image quality and acceptability of a low dose with those of standard dose abdominal/pelvic multidetector CT in patients with stage 1 testicular cancer managed by surveillance...
  37. doi request reprint Major 30-day complications after radical radiotherapy: a population-based analysis and comparison with surgery
    Shabbir M H Alibhai
    Division of General Internal Medicine and Clinical Epidemiology, University Health Network, Toronto, Ontario, Canada
    Cancer 115:293-302. 2009
    ..Few population-based studies have reported on the rates of major short-term complications that lead to hospitalization after radiotherapy...
  38. ncbi request reprint Randomized trial comparing two fractionation schedules for patients with localized prostate cancer
    Himu Lukka
    Radiation Oncology Program, Juravinski Cancer Centre, McMaster University, 699 Concession St, Hamilton, Ontario, Canada, L8V 5C2
    J Clin Oncol 23:6132-8. 2005
    ..The optimal radiation dose fractionation schedule for localized prostate cancer is unclear. This study was designed to compare two dose fractionation schemes (a shorter 4-week radiation schedule v a longer 6.5-week schedule)...
  39. ncbi request reprint Surveillance in stage I testicular seminoma
    Peter Chung
    Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    Urol Oncol 24:75-9. 2006
    ..The possible role of adjuvant chemotherapy is currently being assessed in clinical trials and should not be used outside of a study setting...
  40. ncbi request reprint Radiotherapy alone in patients with advanced nasopharyngeal cancer: comparison with an intergroup study. Is combined modality treatment really necessary?
    Edward Chow
    Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada
    Radiother Oncol 63:269-74. 2002
    ..To examine the outcome of radiotherapy (RT) alone in patients with advanced nasopharyngeal cancer (NPC) and to compare the results with those reported by the Intergroup study 0099 (IGS) comparing RT to combined modality therapy (CMT)...
  41. doi request reprint Utility of serum tumor markers during surveillance for stage I seminoma
    Danny Vesprini
    Department of Radiation Oncology, Sunnybrook Odette Cancer Center, Toronto, Ontario, Canada
    Cancer 118:5245-50. 2012
    ..In this study, the authors evaluated the utility of routine measurement of these markers in the detection of disease relapse...
  42. pmc Treatment-related toxicity and symptom-related bother following postoperative radiotherapy for prostate cancer
    Michael Sia
    Department of Radiation Oncology, The Princess Margaret Hospital and University of Toronto, Toronto, ON
    Can Urol Assoc J 4:105-11. 2010
    ..Patients have reported late effects and symptom-related bother following postoperative radiotherapy for prostate cancer...
  43. ncbi request reprint Testosterone and erectile function recovery after radiotherapy and long-term androgen deprivation with luteinizing hormone-releasing hormone agonists
    Derek R Wilke
    Department of Radiation Oncology, Nova Scotia Cancer Centre, Capital Health, Halifax, Nova Scotia, Canada
    BJU Int 97:963-8. 2006
    ..To study the recovery of testosterone levels and erectile function in men who received radiotherapy plus long-term adjuvant androgen deprivation (LTAD) with luteinizing hormone-releasing hormone (LHRH) agonists...
  44. ncbi request reprint Management of low-stage testicular seminoma
    Mischel Neill
    Division of Urology, Department of Surgery, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada
    Urol Clin North Am 34:127-36; abstract vii-viii. 2007
    ..Radiation therapy remains the mainstay of therapy for patients who have stage IIa disease...
  45. ncbi request reprint The prostate cancer risk stratification project: database construction and risk stratification outcome analysis
    George Rodrigues
    From the aDepartment of Radiation Oncology, London Health Sciences Centre, London, Ontario bDepartment of Radiation Oncology, Juravinski Cancer Centre, Hamilton, Ontario cRadiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario dDepartment of Radiation Oncology, Kingston Regional Cancer Centre, Kingston, Ontario eDepartment of Radiation Oncology, Montreal General Hospital, Montreal, Quebec fDepartment of Radiation Oncology, Kelowna General Hospital, Kelowna, British Columbia gDepartment of Radiation Oncology, L Hôtel Dieu de Québec, Quebec City, Quebec hDepartment of Radiation Oncology, British Columbia Cancer Agency Vancouver Centre, Vancouver, British Columbia, Canada
    J Natl Compr Canc Netw 12:60-9. 2014
    ..The construction of a pan-Canadian database has informed important prostate cancer radiotherapy outcomes and risk stratification. ..
  46. ncbi request reprint Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer
    Chris Parker
    Department of Biostatistics, Princess Margaret Hospital, Toronto, ON, Canada
    Int J Radiat Oncol Biol Phys 58:750-7. 2004
    ..To describe the oxygenation of clinically localized prostate cancer...
  47. doi request reprint Information needs of men on androgen deprivation therapy
    Tony Soeyonggo
    University of Toronto, Toronto, Canada
    BJU Int 109:1503-9. 2012
    ..A key area to enhance patient education appears to be side effects, especially around hot flashes and fatigue, which were also the most bothersome treatment sequelae for patients...
  48. ncbi request reprint The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer - a systematic review
    Michael Brundage
    Kingston Regional Cancer Centre, 25 King Street West, Ontario, Canada
    Radiother Oncol 64:239-50. 2002
    ..are biochemical freedom from failure (bNED) rates, clinical recurrence-free survival, disease-specific survival and acute and late toxicity; (b) what is the appropriate dose and fractionation prescription in this clinical setting?..
  49. ncbi request reprint Recursive partitioning analysis of prognostic factors for survival in patients with advanced cancer
    Edward Chow
    Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
    Int J Radiat Oncol Biol Phys 73:1169-76. 2009
    ..To construct a predictive model for survival of patients referred to the Rapid Response Radiotherapy Program using recursive partitioning (RP)...
  50. ncbi request reprint Pain flare in patients with bone metastases after palliative radiotherapy--a nested randomized control trial
    D Andrew Loblaw
    Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    Support Care Cancer 15:451-5. 2007
    ..The objectives of this study were to determine (1) the incidence of pain flare after palliative radiation for painful osseous metastases, and (2) whether single-fraction radiotherapy increases the risk of pain flare...
  51. ncbi request reprint Contemporary management of stage I and II seminoma
    Peter Chung
    Radiation Medicine Program, Princess Margaret Cancer Centre, 610 University Ave, Toronto, Ontario, M5G 2M9, Canada
    Curr Urol Rep 14:525-33. 2013
    ..For stage II disease, balancing the relative toxicities of radiation and chemotherapy while avoiding the use of multimodality therapy due to the additive long-term toxicity has become the priority. ..
  52. pmc Comparison of localization performance with implanted fiducial markers and cone-beam computed tomography for on-line image-guided radiotherapy of the prostate
    Douglas J Moseley
    Radiation Medicine Program, Princess Margaret Hospital, Toronto, ON, Canada
    Int J Radiat Oncol Biol Phys 67:942-53. 2007
    ....
  53. doi request reprint Stage I seminoma: what should a practicing uro-oncologist do in 2009?
    Julia Skliarenko
    Department of Radiation Oncology, University of Toronto, Princess Margaret Hospital, Toronto, Ontario, Canada
    Int J Urol 16:544-51. 2009
    ..It has been suggested that more patients with stage I seminoma will die of their treatment than of their cancer; therefore, the thrust of modern management should be to maintain 100% cure while minimizing the burden of treatment...
  54. doi request reprint Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer
    John Thoms
    Radiation Medicine Program, Princess Margaret Hospital, University Health Network, 5th Floor, Room 5 808, 610 University Avenue, Toronto, ON M5G 2M9, Canada
    Nat Rev Clin Oncol 8:107-13. 2011
    ..We present the published treatment approaches and rational for preoperative and intraoperative radiotherapy and compare these methods to the utility of postoperative radiotherapy...
  55. ncbi request reprint Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer
    Abbas H Panju
    Department of Medicine, University Health Network, Toronto, Ontario, Canada
    BJU Int 103:753-7. 2009
    ....
  56. doi request reprint Management of stage I testicular seminoma
    Gary Mok
    Radiation Medicine Program, Princess Margaret Hospital, 610 University Avenue, Toronto, ON M5G 2M9, Canada
    Hematol Oncol Clin North Am 25:503-16, vii-iii. 2011
    ..This article reviews the evidence for all adjuvant treatment options for stage I testicular seminomas with a particular focus on surveillance...
  57. ncbi request reprint Limitation of conventional two dimensional radiation therapy planning in nasopharyngeal carcinoma
    John Waldron
    Department of Radiation Oncology, The Princess Margaret Hospital, University of Toronto, 610 University Avenue, Toronto, Ont M5G 2M9, Canada
    Radiother Oncol 68:153-61. 2003
    ..To assess the adequacy of coverage of gross tumor volume (GTV) with traditional two dimensional (2D) radiation therapy (RT) planning in patients with nasopharyngeal cancer (NPC)...
  58. doi request reprint Testicular cancer survivors' supportive care needs and use of online support: a cross-sectional survey
    Jacqueline L Bender
    ELLICSR Health, Wellness and Cancer Survivorship Centre, Toronto General Hospital, 200 Elizabeth Street, Toronto, M5G 2C4, ON, Canada
    Support Care Cancer 20:2737-46. 2012
    ..Likewise, there is limited research on their use of the Internet or social media applications--tools that are popular among young adults and which could be used to address their needs...
  59. ncbi request reprint Low and intermediate risk prostate cancer-- role of hormonal therapy with external beam radiation therapy
    Jarad Martin
    Department of Radiation Oncology, University of Toronto and Radiation Medicine Program, Princess Margaret Hospital, Toronto, Ontario, Canada
    Can J Urol 13:63-7. 2006
    ..However, with appropriate modern dose EBRT there is little data to support the use of routine adjunctive hormonal therapy and this should be done only in the context of a clinical trial...
  60. ncbi request reprint Survey of radiation oncologists: practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States
    Richard Choo
    Department of Radiation Oncology, Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada
    Can J Urol 9:1479-85. 2002
    ..To evaluate practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States...
  61. ncbi request reprint A dose-volume histogram analysis of the seminal vesicles in men treated with conformal radiotherapy to 'prostate alone'
    Christopher Parker
    Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    Clin Oncol (R Coll Radiol) 14:298-302. 2002
    ..To inform the debate, we have undertaken a dose-volume histogram (DVH) analysis of the seminal vesicles in patients treated with escalated dose conformal radiation to 'prostate alone'...
  62. ncbi request reprint Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues
    Alan M Nichol
    Department of Radiation Oncology, University of Toronto and the Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada
    Cancer 104:891-905. 2005
    ..These studies should be stratified by novel prognostic markers and accompanied by strong translational endpoints to address clinical heterogeneity and to allow for individualized treatment...
  63. ncbi request reprint A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma
    Justin Lee
    Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    Cancer 104:1894-900. 2005
    ..The authors conducted a prospective study to assess the effect of RT on symptoms and quality of life (QOL) in patients with metastatic RCC...
  64. ncbi request reprint A reliable coding system to define screening prostate-specific antigen tests was developed in a case-control study
    Peter S Bunting
    Division of Biochemistry, Department of Pathology and Laboratory Medicine, University of Ottawa, Ontario, Canada
    J Clin Epidemiol 58:639-44. 2005
    ..To establish the reliability of a coding system for screening and diagnostic prostate-specific antigen (PSA) testing from patient charts...
  65. doi request reprint Impact of androgen deprivation therapy on cardiovascular disease and diabetes
    Shabbir M H Alibhai
    University Health Network, Room EN14 214, 200 Elizabeth St, Toronto, Ontario, Canada, M5G 2C4
    J Clin Oncol 27:3452-8. 2009
    ..CONCLUSION Continuous ADT use for at least 6 months in older men is associated with an increased risk of diabetes and fragility fracture but not AMI or sudden cardiac death...
  66. ncbi request reprint Controversies in the management of testicular seminoma
    Neil Fleshner
    Division of Urology, Department of Surgery, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    Semin Urol Oncol 20:227-33. 2002
    ..The high failure rate outside the treatment field has now changed this paradigm to one of up-front chemotherapy...
  67. ncbi request reprint The ten-year rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer
    Murray D Krahn
    Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada
    Urology 60:258-63. 2002
    ....
  68. ncbi request reprint Clinical and biochemical outcome of conventional dose radiotherapy for localized prostate cancer
    Charles Catton
    Dept of Radiation Oncology, The Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    Can J Urol 9:1444-52; discussion 1453. 2002
    ..To retrospectively review the results of conventional dose radical radiotherapy for clinical stage T1 and T2 prostate cancer, and to identify the factors that predict the biochemical relapse-free rate...
  69. ncbi request reprint Molecular pathology parameters in human nasopharyngeal carcinoma
    Wei Shi
    Department of Research, Princess Margaret Hospital Ontario Cancer Institute, 610 University Avenue, Toronto, Ontario, M5G 2M9 Canada
    Cancer 94:1997-2006. 2002
    ....
  70. pmc Electronic surveillance of testicular cancer: understanding patient perspectives on access to electronic medical records
    Ryan J Groll
    University Health Network and University of Toronto, Toronto, Ontario, Canada
    J Oncol Pract 5:177-81. 2009
    ..This study explores the basis for providing effective access to electronic medical record data as a reference source for patients with early-stage testicular cancer undergoing surveillance follow-up programs...
  71. ncbi request reprint Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
    Michel Bolla
    University Hospital, Grenoble, France
    Lancet 360:103-6. 2002
    ....
  72. ncbi request reprint Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863
    Fatma Ataman
    EORTC Data Center, Radiotherapy Group, Avenue E Mounier 83, Bte 11, B 1200 Brussels, Belgium
    Eur J Cancer 40:1674-81. 2004
    ..Although four treatment-related deaths (1%) occurred, grade 3 or 4 late complications were less than 5%...
  73. ncbi request reprint Re: Vikram, B., The PSA conundrum. [Radiother Oncol, 2004. 71(1): p. 1-2]
    Kirsty Wiltshire
    Radiother Oncol 73:252-4; author reply 254-5. 2004
  74. doi request reprint European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II
    Susanne Krege
    Department of Urology, Krankenhaus Maria Hilf, Krefeld, Germany
    Eur Urol 53:497-513. 2008
    ..In November 2006, the group met a second time under the auspices of the Department of Urology of the Amsterdam Medical Center, The Netherlands...
  75. doi request reprint European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I
    Susanne Krege
    Department of Urology, Krankenhaus Maria Hilf, Krefeld, Germany
    Eur Urol 53:478-96. 2008
    ..In November 2006, the group met a second time under the auspices of the Department of Urology of the Amsterdam Medical Center, Amsterdam, The Netherlands...
  76. ncbi request reprint A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy
    Andy Trotti
    Radiation Oncology Program, H Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL, USA
    Int J Radiat Oncol Biol Phys 58:674-81. 2004
    ..It is hypothesized that infection plays a role in the development of OM. We tested the efficacy of iseganan HCl (iseganan), a synthetic peptide with broad-spectrum antimicrobial activity, for preventing RT-associated OM...
  77. ncbi request reprint The role of hemoglobin concentration in clinically localized prostate cancer treated with radical radiotherapy +/- neoadjuvant androgen deprivation
    Chris Parker
    Academic Unit of Radiotherapy and Oncology, Institute of Cancer Research and the Royal Marsden NHS Trust, Sutton, Surrey, United Kingdom
    Int J Radiat Oncol Biol Phys 58:53-8. 2004
    ..Serum hemoglobin level (Hb) is a significant determinant of treatment outcome after radical radiotherapy (RT) for several cancer types, but its importance in prostate cancer is not well established...
  78. ncbi request reprint Prostate cancer radiotherapy 2002: the way forward
    Himu Lukka
    Juravinski Cancer Centre, 699 Concession Street, Hamilton, Ontario L8V 5C2, Canada
    Can J Urol 12:2521-31. 2005
    ..Results from ongoing clinical trials will provide insight into these questions and will assist in the design of future clinical trials...
  79. ncbi request reprint Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study
    Jacek A Kopec
    Department of Health Care and Epidemiology, University of British Columbia, Vancouver, Canada
    J Urol 174:495-9; discussion 499. 2005
    ..There is limited evidence that screening is effective in reducing mortality from prostate cancer. In the current study we determined if screening with PSA reduces the risk of metastatic prostate cancer...
  80. ncbi request reprint GU radiation oncologists consensus on bone loss from androgen deprivation
    Graeme G Duncan
    BC Cancer Agency, Vancouver, British Columbia, Canada
    Can J Urol 13:2962-6. 2006
    ..This is now adopted as national practice guidelines for radiation oncologists employed prolonged ADT in prostate cancer patients...
  81. ncbi request reprint Loss of p16 expression has prognostic significance in human nasopharyngeal carcinoma
    Antti A Makitie
    Department of Otolaryngology, Princess Margaret Hospital Ontario Cancer Institute, Toronto M5G 2M9, Canada
    Clin Cancer Res 9:2177-84. 2003
    ..Our objective was to determine whether there was a correlation between these parameters and clinical outcome in NPC...